In partnership with Minnesota Department of Health, Cue’s digital service offers an integrated solution to provide COVID-19 treatment options access across all populations

Agilent Technologies and Qiagen said on Monday and Tuesday respectively that they have gained US Food and Drug Administration approval of companion diagnostic assays for use with a new treatment for patients with advanced non-small cell lung cancer.

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off.

On August 30, Merck announced that the new indication for its nine-valent human papillomavirus vaccine (brewer's yeast) (hereinafter referred to as "nine-valent HPV vaccine") has been approved by National Medical Products Administration.

The Biden administration has been planning for how to get past the crisis phase of the Covid-19 pandemic and will stop buying vaccines, treatments and tests as early as this fall, White House Covid-19 Response Coordinator Dr. Ashish Jha said on Tuesday.

A pair of new studies examines genetic variations that confer risk of developing autism spectrum disorder, providing insight into the different phenotypes associated with the disorder.

August 11, the Second Roche Pan-Tumor Precision Diagnosis and Innovation Ecology Forum was officially opened at Roche Pharma China Shanghai Campus, where participants discussed solutions for pan-tumor precision diagnosis and treatment.

Recently, Wondfo's 2019-nCoV Antigen Test (Lateral Flow Method) is listed by WHO (World Health Organization) for emergency use listing (EUL), available for purchase in other countries and regions in worldwide.

Recently, during the first ZAODX World Cancer Early Screening Conference, Zhu Yeqing, CEO of New Horizon Health Ltd, said that according to CAIVD statistics, there are 58 listed enterprises with IVD business in China by the end of 2021, with a total revenue of 145.032 billion CNY

UK-based startup Tailor Bio has received ￡650,000 ($771,767) through the Innovate UK Biomedical Catalyst Award in support of its ambitions to develop a pan-cancer precision medicine platform.